Effect of renal impairment on the pharmacokinetics of exenatide

@article{Linnebjerg2007EffectOR,
  title={Effect of renal impairment on the pharmacokinetics of exenatide},
  author={Helle Linnebjerg and Prajakti A. Kothare and Soomin Park and Kenneth F. Mace and S. Rajendra Reddy and Malcolm Mitchell and Robert Lins},
  journal={British Journal of Clinical Pharmacology},
  year={2007},
  volume={64},
  pages={317 - 327}
}
AIMS To evaluate the pharmacokinetics (PK), safety and tolerability of a single exenatide dose in patients with renal impairment (RI). METHODS Exenatide (5 or 10 microg) was injected subcutaneously in 31 subjects (one with Type 2 diabetes) stratified by renal function [Cockcroft-Gault creatinine clearance (CrCL), number of subjects]: normal (>80 ml min(-1), n = 8), mild RI (51-80 ml min(-1), n = 8), moderate RI (31-50 ml min(-1), n = 7) or end-stage renal disease (ESRD) requiring… CONTINUE READING
77 Extracted Citations
19 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 77 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 19 references

Pharmacokinetic actions of exendin - 4 in the rat : comparison with glucagon - like peptide - 1

  • D Parkes, C Jodka, +5 authors A Young
  • Drug Dev Res
  • 2006

glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetized pigs

  • D Parkes, C Jodka, +5 authors A. Young
  • Diabetologia
  • 2006

Clinical pharmacokinetics of exenatide in patients with type 2 diabetes

  • S Reddy, S Park, +5 authors PA. Kothare
  • The AAPS J
  • 2005

Similar Papers

Loading similar papers…